Connect with us

Business

Four New IPOs Set to Launch in India Next Week Worth ₹830 Crore

Editorial

Published

on

India’s primary market is gearing up for a bustling week with the launch of four new initial public offerings (IPOs) collectively valued at approximately ₹830 crore. These offerings are set to open for subscription in the third week of December, with significant attention focused on the largest IPO from KSH International, among nearly 15 companies expected to debut.

Investors are particularly keen on the upcoming listing of ICICI Prudential Asset Management Company, which has already shown promising demand. On its first day, subscriptions surpassed the 50% mark, reflecting strong investor interest. In the grey market, the stock is trading at a premium of ₹249, indicating an 11% premium over the IPO price, which suggests positive sentiment surrounding its introduction to the market, according to reports by The Economic Times.

Another noteworthy IPO is from Corona Remedies, which is also witnessing substantial interest, with a grey market premium of about 30%. Nephrocare is trading at a moderate grey market premium of 7%, while Wakefit reflects a marginal premium of around 5%. In the small and medium enterprises (SME) sector, KV Toys stands out with a significant grey market premium of 63%, although other SME offerings are seeing comparatively lower engagement.

KSH International and Neptune Logitek Lead the Charge

The IPO from KSH International is scheduled to open on December 16, 2023, and will close on December 18, 2023. The shares are offered in a price range of ₹365 to ₹384 each, with the total issue size estimated at around ₹710 crore. Shares from this IPO will be listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). Nuvama Wealth Management is managing this high-profile offering, which will play a crucial role in shaping overall market sentiment after a busy issuance calendar in December.

Following closely, Neptune Logitek plans to launch its IPO on December 15, 2023, with subscriptions closing on December 17, 2023. This offering is set at a fixed price of ₹126 and has a total issue size of ₹46.62 crore. The listing will occur on the BSE SME platform, with Galactico Corporate Advisors serving as the lead manager for the issue.

Additional Offerings and Market Outlook

Later in the week, MARC Technocrats will open its IPO on December 17, 2023, closing on December 19, 2023. This issue, valued at ₹42.59 crore, is priced between ₹88 to ₹93 per share and will be listed on the NSE SME platform, with Narnolia Financial Services as the book-running lead manager. On the same day, Global Ocean Logistics India will also commence its IPO, offering shares priced between ₹74 to ₹78, with a total issue size of ₹30.41 crore, to be listed on the BSE SME exchange and managed by Marwadi Chandarana Intermediaries.

As the week unfolds, the focus will shift to these significant IPOs, particularly with the anticipated high-profile listings of ICICI Prudential AMC, Corona Remedies, and Park Medi World. With the market crowded by approximately 15 companies making their entries, next week is set to be one of the busiest periods for public offerings this year. Investors are likely to keep a close eye on these developments, which could influence market trends as December progresses.

Our Editorial team doesn’t just report the news—we live it. Backed by years of frontline experience, we hunt down the facts, verify them to the letter, and deliver the stories that shape our world. Fueled by integrity and a keen eye for nuance, we tackle politics, culture, and technology with incisive analysis. When the headlines change by the minute, you can count on us to cut through the noise and serve you clarity on a silver platter.

Continue Reading

Trending

Copyright © All rights reserved. This website offers general news and educational content for informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the information provided. The content should not be considered professional advice of any kind. Readers are encouraged to verify facts and consult relevant experts when necessary. We are not responsible for any loss or inconvenience resulting from the use of the information on this site.